Yaqiang Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yaqiang Huang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Hao Yang
Department of Urology, Zhongshan City People’s Hospital, Zhongshan, China
3 shared publicationsHongxing Huang
Department of Urology, Zhongshan City People’s Hospital, Zhongshan, China
3 shared publicationsQi Wang
Department of Urology, Zhongshan City People’s Hospital, Zhongshan, China
3 shared publicationsWeiyang Wei
Department of Urology, Zhongshan City People’s Hospital, Zhongshan, China
3 shared publicationsChuanpeng Zhou
Department of Urology, Zhongshan City People’s Hospital, Zhongshan, China
2 shared publications- Xinxiang Fan
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, P. R. China
2 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Springer Nature in BMC Medical Imaging
- Vol. 26 (1)
Unlocking the prognostic power of pathomics in bladder cancer: a machine learning odyssey across multiple centers
Bladder cancer (BCa) prognostication is pivotal for tailored clinical interventions. Using machine learning, this study assesses prognostic capabilities of H&E-stained BCa images. From 569 slides across The Cancer Genome Atlas, Sun Yat-sen Memorial Hospital, and Zhongshan City People’s Hospital, we extracted 150 histopathological markers each. LASSO regression yielded a pathomic fingerprint, which was further validated. An integrated model, fusing this fingerprint with salient clinicopathological indicators, displayed notable efficacy in both training (C-index: 0.658) and validation cohorts (C-index: 0.590–0.597). Incorporating the fingerprint, age, and N stage, the model excelled in training (C-index: 0.703) and validations (C-index: 0.612–0.646). Decision curve analysis underscored its clinical relevance. Conclusively, our pathomic-clinical framework offers advanced precision in BCa patient prognosis, enhancing clinical decision-making.
- 14 April 2026
- Published by Springer Nature in BMC Medical Imaging
- Vol. 26 (1)
Open AccessUnlocking the prognostic power of pathomics in bladder cancer: a machine learning odyssey across multiple centers
Bladder cancer (BCa) prognostication is pivotal for tailored clinical interventions. Using machine learning, this study assesses prognostic capabilities of H&E-stained BCa images. From 569 slides across The Cancer Genome Atlas, Sun Yat-sen Memorial Hospital, and Zhongshan City People’s Hospital, we extracted 150 histopathological markers each. LASSO regression yielded a pathomic fingerprint, which was further validated. An integrated model, fusing this fingerprint with salient clinicopathological indicators, displayed notable efficacy in both training (C-index: 0.658) and validation cohorts (C-index: 0.590–0.597). Incorporating the fingerprint, age, and N stage, the model excelled in training (C-index: 0.703) and validations (C-index: 0.612–0.646). Decision curve analysis underscored its clinical relevance. Conclusively, our pathomic-clinical framework offers advanced precision in BCa patient prognosis, enhancing clinical decision-making.
- Open Access
- 15 October 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-10
Integrating urinary dual-gene methylation and VI-RADS score to predict residual tumors after TURBT in NMIBC: a nomogram-based model
Bladder cancer (BC) is the ninth most prevalent cancer globally, with approximately 75% of cases classified as non-muscle-invasive bladder cancer (NMIBC). Although transurethral resection of bladder tumor (TURBT) is the standard treatment for NMIBC, there remains a considerable risk of postoperative residual tumors. Accurately identifying patients who require repeat transurethral resection of bladder tumor (Re-TURBT) remains a significant clinical challenge. Magnetic resonance imaging (MRI) exhibits high accuracy in detecting residual tumors after TURBT, aiding clinical decision-making. However, its relatively low specificity limits its clinical applicability. Urinary methylation markers, particularly those associated with H4 cluster protein 6 (H4C6) and Twist Family BHLH Transcription Factor 1 (TWIST1), have demonstrated high sensitivity and specificity in detecting bladder cancer, showing promising clinical performance. The combined detection of H4C6 and TWIST1 gene methylation provides a more reliable method for identifying residual tumors post-TURBT. Integrating the VI-RADS score with urine gene methylation analysis could complement each other, improving the accuracy of residual tumor detection and enhancing clinical applicability. This study aimed to evaluate the predictive value of clinical/pathological factors, urinary H4C6 and TWIST1 gene methylation, and their combined performance in identifying postoperative residual tumors in NMIBC patients. Morning urine samples from NMIBC patients at Zhongshan City People’s Hospital (June 2022–August 2024) were analyzed for H4C6 and TWIST1 methylation levels. Patients underwent MRI and Re-TURBT. Logistic regression was used to identify predictors of residual tumors, and a nomogram was developed. Model performance was evaluated using Receiver Operating Characteristic (ROC) curves and decision curve analysis (DCA). Among the 55 patients included in the study, the area under the ROC curve (AUC) for urinary H4C6 methylation was 0.698, whereas TWIST1 methylation had an AUC of 0.758. Combined dual-gene methylation yielded an AUC of 0.764. The AUC for VI-RADS scoring was 0.888. When dual-gene methylation and hematuria were combined with VI-RADS scores, the prediction model achieved an AUC of 0.972. DCA demonstrated that the prediction model offers substantial clinical benefit across a broad range of threshold probabilities. The combined prediction model of dual-gene methylation, hematuria, and VI-RADS scores offers a powerful non-invasive method to assist clinicians in identifying high-risk patients with residual tumors after TURBT, thereby reducing unnecessary Re-TURBT and improving patient management. Urinary H4C6 and TWIST1 gene methylation, along with VI-RADS scoring, show high diagnostic performance in predicting residual tumors following TURBT in NMIBC patients. A combined prediction model incorporating dual-gene methylation, hematuria, and VI-RADS scores achieves superior discrimination, excellent calibration, and strong clinical utility.
- 15 October 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-10
Open AccessIntegrating urinary dual-gene methylation and VI-RADS score to predict residual tumors after TURBT in NMIBC: a nomogram-based model
Bladder cancer (BC) is the ninth most prevalent cancer globally, with approximately 75% of cases classified as non-muscle-invasive bladder cancer (NMIBC). Although transurethral resection of bladder tumor (TURBT) is the standard treatment for NMIBC, there remains a considerable risk of postoperative residual tumors. Accurately identifying patients who require repeat transurethral resection of bladder tumor (Re-TURBT) remains a significant clinical challenge. Magnetic resonance imaging (MRI) exhibits high accuracy in detecting residual tumors after TURBT, aiding clinical decision-making. However, its relatively low specificity limits its clinical applicability. Urinary methylation markers, particularly those associated with H4 cluster protein 6 (H4C6) and Twist Family BHLH Transcription Factor 1 (TWIST1), have demonstrated high sensitivity and specificity in detecting bladder cancer, showing promising clinical performance. The combined detection of H4C6 and TWIST1 gene methylation provides a more reliable method for identifying residual tumors post-TURBT. Integrating the VI-RADS score with urine gene methylation analysis could complement each other, improving the accuracy of residual tumor detection and enhancing clinical applicability. This study aimed to evaluate the predictive value of clinical/pathological factors, urinary H4C6 and TWIST1 gene methylation, and their combined performance in identifying postoperative residual tumors in NMIBC patients. Morning urine samples from NMIBC patients at Zhongshan City People’s Hospital (June 2022–August 2024) were analyzed for H4C6 and TWIST1 methylation levels. Patients underwent MRI and Re-TURBT. Logistic regression was used to identify predictors of residual tumors, and a nomogram was developed. Model performance was evaluated using Receiver Operating Characteristic (ROC) curves and decision curve analysis (DCA). Among the 55 patients included in the study, the area under the ROC curve (AUC) for urinary H4C6 methylation was 0.698, whereas TWIST1 methylation had an AUC of 0.758. Combined dual-gene methylation yielded an AUC of 0.764. The AUC for VI-RADS scoring was 0.888. When dual-gene methylation and hematuria were combined with VI-RADS scores, the prediction model achieved an AUC of 0.972. DCA demonstrated that the prediction model offers substantial clinical benefit across a broad range of threshold probabilities. The combined prediction model of dual-gene methylation, hematuria, and VI-RADS scores offers a powerful non-invasive method to assist clinicians in identifying high-risk patients with residual tumors after TURBT, thereby reducing unnecessary Re-TURBT and improving patient management. Urinary H4C6 and TWIST1 gene methylation, along with VI-RADS scoring, show high diagnostic performance in predicting residual tumors following TURBT in NMIBC patients. A combined prediction model incorporating dual-gene methylation, hematuria, and VI-RADS scores achieves superior discrimination, excellent calibration, and strong clinical utility.
- Open Access
- 27 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Comparison of mini-percutaneous nephrolithotomy and standard percutaneous nephrolithotomy in the treatment of renal calculi with renal insufficiency
To compare the clinical efficacy and safety of mini-percutaneous nephrolithotomy (MPCNL) and standard percutaneous nephrolithotomy (SPCNL) in the treatment of kidney stones combine with renal insufficiency. The data of 320 patients with renal calculi and an eGFR < 60 mL/min/1.73m2 who underwent percutaneous nephrolithotomy (PCNL) at Zhongshan City People’s Hospital from January 2018 to June 2023 were retrospectively analyzed; 164 patients were treated with MPCNL, and 156 were treated with SPCNL. The clinical efficacy of the MPCNL and SPCNL regimens was compared in terms of stone-free rate (SFR), renal function change, hemoglobin (HGB) drop and other complication rates (complications were classified by using the Clavien‒Dindo system). The SFR was 67.1% in the MPCNL group and 67.9% in the SPCNL group (P = 0.867). The overall eGFR of the two groups was significantly improved at 1 month after the operation (P < 0.001). Postoperative renal function was stable, improved and worse in 50.0% (n = 82) vs. 53.8% (n = 84), 39.0% (n = 64) vs. 42.4% (n = 66) and 11.0% (n = 18) vs. 3.8% (n = 6) of the MPCNL and SPCNL patients, respectively, compared with preoperative renal function (P = 0.053). In addition, the overall postoperative complication rates between the two groups was not significantly different (P = 0.103). Patients who underwent MPCNL had a lower transfusion rate (7.9% vs. 16.7%, P = 0.017) and shorter hospital stay (4.57 ± 3.14 vs. 7.16 ± 4.05 days, P < 0.001) than those in the SPCNL group. MPCNL and SPCNL have positive effects on the treatment of renal calculi in patients with renal insufficiency; both have acceptable SFRs and complication rates, stable or improved renal function in most patients.
- 27 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessComparison of mini-percutaneous nephrolithotomy and standard percutaneous nephrolithotomy in the treatment of renal calculi with renal insufficiency
To compare the clinical efficacy and safety of mini-percutaneous nephrolithotomy (MPCNL) and standard percutaneous nephrolithotomy (SPCNL) in the treatment of kidney stones combine with renal insufficiency. The data of 320 patients with renal calculi and an eGFR < 60 mL/min/1.73m2 who underwent percutaneous nephrolithotomy (PCNL) at Zhongshan City People’s Hospital from January 2018 to June 2023 were retrospectively analyzed; 164 patients were treated with MPCNL, and 156 were treated with SPCNL. The clinical efficacy of the MPCNL and SPCNL regimens was compared in terms of stone-free rate (SFR), renal function change, hemoglobin (HGB) drop and other complication rates (complications were classified by using the Clavien‒Dindo system). The SFR was 67.1% in the MPCNL group and 67.9% in the SPCNL group (P = 0.867). The overall eGFR of the two groups was significantly improved at 1 month after the operation (P < 0.001). Postoperative renal function was stable, improved and worse in 50.0% (n = 82) vs. 53.8% (n = 84), 39.0% (n = 64) vs. 42.4% (n = 66) and 11.0% (n = 18) vs. 3.8% (n = 6) of the MPCNL and SPCNL patients, respectively, compared with preoperative renal function (P = 0.053). In addition, the overall postoperative complication rates between the two groups was not significantly different (P = 0.103). Patients who underwent MPCNL had a lower transfusion rate (7.9% vs. 16.7%, P = 0.017) and shorter hospital stay (4.57 ± 3.14 vs. 7.16 ± 4.05 days, P < 0.001) than those in the SPCNL group. MPCNL and SPCNL have positive effects on the treatment of renal calculi in patients with renal insufficiency; both have acceptable SFRs and complication rates, stable or improved renal function in most patients.
- 1 April 2025
- Published by Springer Nature in Drugs
- Vol. 85 (5) , 677-693
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Background Neurogenic lower urinary tract dysfunction (NLUTD), a complex abnormality caused by multiple neurologic disorders, is a serious threat to patients’ prognosis and quality of life. However, benefit and safety for various treatments are inconsistent. The aim of the current study was to investigate the available trials of adult NLUTD treatments and provide valuable insights for clinical practice. Methods The data sources were Medline, Embase, and Cochrane databases up to 31 December 2023. A Bayesian network meta-analysis was conducted with randomized controlled trials in patients who were diagnosed with NLUTD, reporting clinical symptoms and urodynamic data. The main outcomes were incontinence episodes frequency (IEF) and maximum cystometric capacity (MCC). Secondary outcomes included frequency, maximum detrusor pressure, bladder compliance, volume of involuntary detrusor contraction, voided volume, incontinence, quality of life, and adverse events. Results A total of 54 articles were eligible, evaluating 28 treatments and 4478 patients for efficacy and safety. Compared with the control group, the oxybutynin instillation demonstrated a mean reduction in IEF of − 2.65 episodes (95% confidence interval [CI]: − 4.64 to − 0.67), with a surface under the cumulative ranking curve (SUCRA) value of 85.8%. Botulinum toxin trigone-combined injection resulted in a reduction of -2.30 episodes (95% CI: -3.23 to - 1.44; SUCRA 84.2%). Additionally, intravesical therapies significantly increased MCC: oxybutynin instillation (mean 227.75 mL, 95% CI 147.00 to 311.42, SUCRA 99.1%) and BTX300U (mean 147.88 mL, 95% CI 100.45–190.32, SUCRA 83.2%). Botulinum toxin injection emerged as the preferred option for improving most urodynamic outcomes and quality of life. However, the incidence of adverse events associated with intravesical injections was higher compared with oral medications and other noninvasive therapies. The three types of botulinum toxins (onabotulinum toxin, abobotulinum toxin, and incobotulinum toxin) demonstrated consistent efficacy in treating both IEF and MCC. Individual studies were sequentially excluded for analysis of network stability. Most results from the alternative networks were consistent with the original analysis, although specific trials influenced certain therapy rankings. Conclusions Overall, oxybutynin instillation and intravesical botulinum toxin injection demonstrated significant advantages in improving symptoms and urodynamic parameters. Our findings support intravesical treatment as a safe and effective option, provided that patients are fully informed about their treatment choices. Clinically, intravesical therapies, oral medications, nerve stimulation, and other treatments should be integrated into shared decision-making processes, while some options require further research to bolster the supporting evidence.
- 1 April 2025
- Published by Springer Nature in Drugs
- Vol. 85 (5) , 677-693
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Background Neurogenic lower urinary tract dysfunction (NLUTD), a complex abnormality caused by multiple neurologic disorders, is a serious threat to patients’ prognosis and quality of life. However, benefit and safety for various treatments are inconsistent. The aim of the current study was to investigate the available trials of adult NLUTD treatments and provide valuable insights for clinical practice. Methods The data sources were Medline, Embase, and Cochrane databases up to 31 December 2023. A Bayesian network meta-analysis was conducted with randomized controlled trials in patients who were diagnosed with NLUTD, reporting clinical symptoms and urodynamic data. The main outcomes were incontinence episodes frequency (IEF) and maximum cystometric capacity (MCC). Secondary outcomes included frequency, maximum detrusor pressure, bladder compliance, volume of involuntary detrusor contraction, voided volume, incontinence, quality of life, and adverse events. Results A total of 54 articles were eligible, evaluating 28 treatments and 4478 patients for efficacy and safety. Compared with the control group, the oxybutynin instillation demonstrated a mean reduction in IEF of − 2.65 episodes (95% confidence interval [CI]: − 4.64 to − 0.67), with a surface under the cumulative ranking curve (SUCRA) value of 85.8%. Botulinum toxin trigone-combined injection resulted in a reduction of -2.30 episodes (95% CI: -3.23 to - 1.44; SUCRA 84.2%). Additionally, intravesical therapies significantly increased MCC: oxybutynin instillation (mean 227.75 mL, 95% CI 147.00 to 311.42, SUCRA 99.1%) and BTX300U (mean 147.88 mL, 95% CI 100.45–190.32, SUCRA 83.2%). Botulinum toxin injection emerged as the preferred option for improving most urodynamic outcomes and quality of life. However, the incidence of adverse events associated with intravesical injections was higher compared with oral medications and other noninvasive therapies. The three types of botulinum toxins (onabotulinum toxin, abobotulinum toxin, and incobotulinum toxin) demonstrated consistent efficacy in treating both IEF and MCC. Individual studies were sequentially excluded for analysis of network stability. Most results from the alternative networks were consistent with the original analysis, although specific trials influenced certain therapy rankings. Conclusions Overall, oxybutynin instillation and intravesical botulinum toxin injection demonstrated significant advantages in improving symptoms and urodynamic parameters. Our findings support intravesical treatment as a safe and effective option, provided that patients are fully informed about their treatment choices. Clinically, intravesical therapies, oral medications, nerve stimulation, and other treatments should be integrated into shared decision-making processes, while some options require further research to bolster the supporting evidence.
- 27 March 2024
- Published by S. Karger AG in Urologia Internationalis
- Vol. 108 (4) , 334-338
Safety and Feasibility of Single-Port Nephroscopy Combined with a Needle Electrode Technique to Treat Dorsal Simple Renal Cysts
Introduction: The aim of this study was to explore the safety and feasibility of single-port nephroscopy combined with a needle electrode technique to unroof single dorsal simple renal cysts (SRCs). Methods: This was a retrospective analysis of the clinical data for 18 patients with single dorsal SRCs treated with single-port nephroscopy and a needle electrode technique at Zhongshan City People’s Hospital from August 2021 to August 2022. The basic information included the cyst condition, surgical methods and recurrence rate, and follow-up was conducted with CT imaging. Results: The surgery was successful in all 18 patients. The duration of surgery ranged from 24 to 46 min, with an average of 35.83 ± 1.62 min; the intraoperative bleeding volume ranged from 2 to 20 mL, with an average of 9.0 ± 1.3 mL; and the visual analog scale (VAS) score within 24 h after surgery ranged from 1 to 6 points, with an average of 2.72 ± 0.36 points. There were no significant postoperative complications, such as bleeding, urinary fistula, or infection. All drainage tubes were removed on the first day after surgery. After 1 year of postoperative follow-up, 1 patient experienced recurrence, for a recurrence rate of 5.6%. Conclusion: Single-port nephroscopy combined with a needle electrode technique is a safe, feasible, and effective minimally invasive surgical approach for treating single dorsal SRCs.
- 27 March 2024
- Published by S. Karger AG in Urologia Internationalis
- Vol. 108 (4) , 334-338
Safety and Feasibility of Single-Port Nephroscopy Combined with a Needle Electrode Technique to Treat Dorsal Simple Renal Cysts
Introduction: The aim of this study was to explore the safety and feasibility of single-port nephroscopy combined with a needle electrode technique to unroof single dorsal simple renal cysts (SRCs). Methods: This was a retrospective analysis of the clinical data for 18 patients with single dorsal SRCs treated with single-port nephroscopy and a needle electrode technique at Zhongshan City People’s Hospital from August 2021 to August 2022. The basic information included the cyst condition, surgical methods and recurrence rate, and follow-up was conducted with CT imaging. Results: The surgery was successful in all 18 patients. The duration of surgery ranged from 24 to 46 min, with an average of 35.83 ± 1.62 min; the intraoperative bleeding volume ranged from 2 to 20 mL, with an average of 9.0 ± 1.3 mL; and the visual analog scale (VAS) score within 24 h after surgery ranged from 1 to 6 points, with an average of 2.72 ± 0.36 points. There were no significant postoperative complications, such as bleeding, urinary fistula, or infection. All drainage tubes were removed on the first day after surgery. After 1 year of postoperative follow-up, 1 patient experienced recurrence, for a recurrence rate of 5.6%. Conclusion: Single-port nephroscopy combined with a needle electrode technique is a safe, feasible, and effective minimally invasive surgical approach for treating single dorsal SRCs.
- Open Access
- 13 February 2024
- Published by Springer Nature in Research Square
Comparison of mini-percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy for patients with kidney stones and renal insufficiency: A retrospective study
Objective To compare the clinical efficacy and safety of mini-percutaneous nephrolithotomy (MPCNL) and standard percutaneous nephrolithotomy (SPCNL) in the treatment of kidney stones combine with renal insufficiency. Patients and Methods: The data of 320 patients with renal calculi and an eGFR < 60 mL/min/1.73m2 who underwent percutaneous nephrolithotomy (PCNL) at Zhongshan City People's Hospital from January 2018 to June 2023 were retrospectively analyzed; 164 patients were treated with MPCNL, and 156 were treated with SPCNL. The clinical efficacy of the MPCNL and SPCNL regimens was compared in terms of stone-free rate (SFR), renal function change, hemoglobin (HGB) drop and other complication rates (complications were classified by using the Clavien‒Dindo system). Results The SFR was 67.1% in the MPCNL group and 67.9% in the SPCNL group (P = 0.867). The overall eGFR of the two groups was significantly improved at 1 month after the operation (P < 0.001). Postoperative renal function was stable, improved and worse in 50.0% (n = 82) vs. 53.8% (n = 84), 39.0% (n = 64) vs. 42.4% (n = 66) and 11.0% (n = 18) vs. 3.8% (n = 6) of the MPCNL and SPCNL patients, respectively, compared with preoperative renal function (P = 0.053). In addition, the overall postoperative complication rates between the two groups was not significantly different (P = 0.103). Patients who underwent MPCNL had a lower transfusion rate (7.9% vs. 16.7%, P = 0.017) and shorter hospital stay (4.57 ± 3.14 vs. 7.16 ± 4.05 days, P < 0.001) than those in the SPCNL group. Conclusion MPCNL and SPCNL have positive effects on the treatment of renal calculi in patients with renal insufficiency; both have acceptable SFRs and complication rates, stable or improved renal function in most patients.
- 13 February 2024
- Published by Springer Nature in Research Square
Open AccessComparison of mini-percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy for patients with kidney stones and renal insufficiency: A retrospective study
Objective To compare the clinical efficacy and safety of mini-percutaneous nephrolithotomy (MPCNL) and standard percutaneous nephrolithotomy (SPCNL) in the treatment of kidney stones combine with renal insufficiency. Patients and Methods: The data of 320 patients with renal calculi and an eGFR < 60 mL/min/1.73m2 who underwent percutaneous nephrolithotomy (PCNL) at Zhongshan City People's Hospital from January 2018 to June 2023 were retrospectively analyzed; 164 patients were treated with MPCNL, and 156 were treated with SPCNL. The clinical efficacy of the MPCNL and SPCNL regimens was compared in terms of stone-free rate (SFR), renal function change, hemoglobin (HGB) drop and other complication rates (complications were classified by using the Clavien‒Dindo system). Results The SFR was 67.1% in the MPCNL group and 67.9% in the SPCNL group (P = 0.867). The overall eGFR of the two groups was significantly improved at 1 month after the operation (P < 0.001). Postoperative renal function was stable, improved and worse in 50.0% (n = 82) vs. 53.8% (n = 84), 39.0% (n = 64) vs. 42.4% (n = 66) and 11.0% (n = 18) vs. 3.8% (n = 6) of the MPCNL and SPCNL patients, respectively, compared with preoperative renal function (P = 0.053). In addition, the overall postoperative complication rates between the two groups was not significantly different (P = 0.103). Patients who underwent MPCNL had a lower transfusion rate (7.9% vs. 16.7%, P = 0.017) and shorter hospital stay (4.57 ± 3.14 vs. 7.16 ± 4.05 days, P < 0.001) than those in the SPCNL group. Conclusion MPCNL and SPCNL have positive effects on the treatment of renal calculi in patients with renal insufficiency; both have acceptable SFRs and complication rates, stable or improved renal function in most patients.
- Open Access
- 29 August 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 90
Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer
The NIMA-related kinase 2 (NEK2) is a serine/threonine kinase that is involved in regulation of centrosome duplication and spindle assembly during mitosis. Dysregulation of these processes causes chromosome instability and aneuploidy, which are hallmark changes of many solid tumors. However, whether aberrant expression of NEK2 is associated with outcome of prostate cancer (PCa) patients remains to be determined. Expression of NEK2 in human PCa cells and primary PCa tissues was assessed by quantitative RT-PCR. Expression of NEK2 in human PCa cells was depleted with siRNA. Effects of the depletion on cell proliferation, survival, and tumorigenicity were assessed both in vitro with cell cultures and in vivo with subcutaneous implantation of xenografts. In silico analyses of the online Taylor dataset were carried out to determine whether the expression level of NEK2 correlated with the clinicopathological characteristics of prostate cancer. Compared with benign human prostatic epithelial cells and tissues, the expression of NEK2 was elevated in human PCa cells and primary PCa tissues. Depleting NEK2 expression inhibited human PCa cell proliferation in vitro and xenograft growth in vivo. Expression level of NEK2 in PCa positively correlated with the Gleason score and pathologic stage of the patient. The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa prognosis. Further validation with large sample pool is warrant.
- 29 August 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 90
Open AccessOverexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer
The NIMA-related kinase 2 (NEK2) is a serine/threonine kinase that is involved in regulation of centrosome duplication and spindle assembly during mitosis. Dysregulation of these processes causes chromosome instability and aneuploidy, which are hallmark changes of many solid tumors. However, whether aberrant expression of NEK2 is associated with outcome of prostate cancer (PCa) patients remains to be determined. Expression of NEK2 in human PCa cells and primary PCa tissues was assessed by quantitative RT-PCR. Expression of NEK2 in human PCa cells was depleted with siRNA. Effects of the depletion on cell proliferation, survival, and tumorigenicity were assessed both in vitro with cell cultures and in vivo with subcutaneous implantation of xenografts. In silico analyses of the online Taylor dataset were carried out to determine whether the expression level of NEK2 correlated with the clinicopathological characteristics of prostate cancer. Compared with benign human prostatic epithelial cells and tissues, the expression of NEK2 was elevated in human PCa cells and primary PCa tissues. Depleting NEK2 expression inhibited human PCa cell proliferation in vitro and xenograft growth in vivo. Expression level of NEK2 in PCa positively correlated with the Gleason score and pathologic stage of the patient. The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa prognosis. Further validation with large sample pool is warrant.